Clinical trials: Recurrent Epithelial Ovarian Cancer
Advanced Malignant Mesothelioma, Carcinoma of the Appendix
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RATIONALE: An orientation and patient education program and telephone counseling may help improve the quality of life in patients with peritoneal surface malignancies.
- Conditions
- Advanced Malignant Mesothelioma, Carcinoma of the Appendix, Ovarian Sarcoma, Ovarian Stromal Cancer
- Trial name
- HOPE (NCT01126346)
- Testing
- HIPEC Orientation, Consultation with Survivorship Navigator, Questionnaires
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Ovarian Cancer
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with autologous peripheral stem cell transplantation may allow the doctor to give…
- Trial name
- ETC (NCT00005612)
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Fallopian Tube Cancer, Ovarian Cancer
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy such as carboplatin use different ways to stop tumor cells from dividing so they stop…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00028912
- Testing
- bortezomib, carboplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
This phase I trial is studying how well ipilimumab works after allogeneic stem cell transplant in treating patients with persistent or progressive cancer.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00060372
- Testing
- ipilimumab, therapeutic allogeneic lymphocytes
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Recurrent Platinum-sensitive Ovarian Cancer
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.
- Trial name
- NCT01837251
- Testing
- Carboplatin, PLD, Bevacizumab
- Where
- 193 sites in Australia, Austria and 4 more
- Volunteers
- 682 people
- Sponsor
- AGO Research GmbH
Ovarian Cancer, Recurrent Ovarian Carcinoma
A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results
In ovarian cancer (OC), complete surgical debulking and platinum-based chemotherapy are the standard treatment, now followed by maintenance therapy with PARP inhibitors or Bevacizumab.
- Trial name
- FOFU (NCT06541171)
- Testing
- Magnetic resonance imaging as fpr clinical practice
- Where
- Italy
- Volunteers
- 220 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03552471
- Testing
- Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Ovarian Cancer, Fallopian Tube Cancers
Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer
Efficacy and safety of Benmelstobart combined with Anlotinib and oral metronomic Cyclophosphamide in the treatment of recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (BACON study) in China
- Conditions
- Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
- Trial name
- BACON (NCT07489300)
- Testing
- Benmelstobart in combination with Anlotinib and oral metronomic Cyclophosphamide
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients who have recurrent…
- Trial name
- NCT00005029
- Testing
- topotecan hydrochloride
- Where
- 74 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Recurrent Ovarian Cancer
An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer
Clinical trials are, due to the inclusion and exclusion criteria, accomplished with defined patient groups, which are not representative for the whole patient population.
- Trial name
- NIS-OvaYond (NCT01869400)
- Where
- 2 sites in Germany
- Volunteers
- 83 people
- Sponsor
- PharmaMar, Spain
Adnexal Mass, Borderline Ovarian Epithelial Tumor
Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer
This pilot research trial studies folate receptor in diagnosing ovarian cancer using serum samples from patients with a newly diagnosed pelvic mass or previously diagnosed ovarian cancer.
- Conditions
- Adnexal Mass, Borderline Ovarian Epithelial Tumor, Ovarian Clear Cell Tumor, Ovarian Endometrioid Tumor
- Trial name
- NCT02520115
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Valproic Acid
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Ovarian Cancer, Fallopian Tube Carcinoma
SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
This study is an open-label, dose-escalation, investigator-initiated phase I interventional clinical study. To evaluate the safety, tolerability and preliminary efficacy of SCT-001 CAR-T cell injection in subjects with relapsed…
- Conditions
- Ovarian Cancer, Fallopian Tube Carcinoma, Peritoneal Carcinoma
- Trial name
- NCT06846424
- Testing
- SCT-001 CAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Recurrent, Platinum-resistant
"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is a phase I clinical study for patients with platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal cancer, and the response to a combination of cyclophosphamide, autologous tumor-infiltrating…
- Conditions
- Recurrent, Platinum-resistant, High Grade Serous Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT01883297
- Testing
- Re-stimulated tumor-infiltrating lymphocytes (TILs), Interleukin-2, Cyclophosphamide
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- University Health Network, Toronto
Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination.
- Trial name
- CHARGE (NCT04315233)
- Testing
- Ribociclib, Belinostat
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Endometrial Cancer, Ovarian Cancer
Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have advanced…
- Conditions
- Endometrial Cancer, Ovarian Cancer, Sarcoma
- Trial name
- NCT00003718
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Recurrent Ovarian Carcinoma
Helping Ovarian Cancer Patients Cope With Their Illness (HOPE)
This clinical trial compares the effect of the Helping Ovarian Cancer Patients Cope with Their Disease (HOPE) intervention to usual care for the reduction of hopelessness and helplessness in patients with ovarian cancer that has…
- Trial name
- NCT06666218
- Testing
- Behavioral Intervention, Electronic Health Record Review, Interview
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This phase II trial is studying how well giving bevacizumab together with erlotinib works in treating patients with recurrent or metastatic ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer.
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Trial name
- NCT00126542
- Testing
- bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Ovarian Cancer, Fallopian Tube Cancer
A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers
The primary objective of this study is to investigate the feasibility, tolerability and safety of surgical debulking and resection with heated intraoperative chemotherapy (HIPEC) followed by repeated intraperitoneal chemotherapy…
- Trial name
- HIPEC (NCT01659554)
- Testing
- Cisplatin, Doxorubicin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University
Platinum-resistant Ovarian Cancer (PROC), Immunotherapy
Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer
The investigators explore the efficacy and safety of adebrelimab (PD-L1 inhibitor) plus Non-platinum chemotherapy and Fuzuloparib (PARP inhibitor) induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib…
- Trial name
- NCT06600841
- Testing
- Immunotherapy（Adebrelimab）
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fujian Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.